26PD FORETINIB (GSK1363089), A MULTIKINASE INHIBITOR OF MET AND VEGFS, OVERCOMES RESISTANCE TO BEVACIZUMAB IN AN IN VIVO MODEL OF ACQUIRED BEVACIZUMAB RESISTANCE

tumors had a significantly higher miRNA risk-score than subjects with benign nodules or healthy controls (p-value <0.0001). MiRNA signature had an higher sensitivity than CT/PET (63% versus 53%), particularly among subjects with non-solid nodules (64% versus 18%). The combination of CT/PET and miRNA test correctly classified 83% of tumors. MiRNA and CT/PET specificity was 100% and 92%, respectively. We did not found any statistically significant association between the miRNA risk-score and clinical or radiological characteristics both for tumors and benign nodules. Conclusions: MiRNA risk-score had a higher sensitivity than CT/PET in screen-detected lung cancers. A combination of miRNA test and CT/PET should be prospectively evaluated to optimize the workup for suspicious screen-detected nodules and to reduce the false positive cases at surgery. Disclosure: All authors have declared no conflicts of interest.